Arrowhead Pharmaceuticals (NASDAQ:ARWR) PT Lowered to $27.00 at Morgan Stanley

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its target price lowered by Morgan Stanley from $36.00 to $27.00 in a research report report published on Monday morning, Benzinga reports. The brokerage currently has an equal weight rating on the biotechnology company’s stock. A number of other equities research analysts have also recently weighed in on […]

Leave a Reply

Your email address will not be published.

Previous post Duff & Phelps Utility and Infrastructure Fund Inc. (NYSE:DPG) Shares Sold by Truist Financial Corp
Next post Service Properties Trust (NASDAQ:SVC) Given New $9.00 Price Target at B. Riley